Bortezomib-Induced Lupus Erythematosus Tumidus
Open Access
- 27 May 2009
- journal article
- case report
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 14 (6) , 637-639
Abstract
This paper reports on an exceptional case of lupus erythematosus tumidus induced by bortezomib during the treatment of multiple myeloma.Keywords
This publication has 17 references indexed in Scilit:
- Bortezomib-Induced Skin EruptionDermatology, 2008
- Bortezomib-associated cutaneous vasculitisBritish Journal of Dermatology, 2007
- Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?British Journal of Haematology, 2006
- Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro‐inflammatory cytokinesEuropean Journal of Haematology, 2006
- Bortezomib-Induced Skin LesionsNew England Journal of Medicine, 2005
- Lupus erythematosus tumidus: a series of 26 casesInternational Journal of Dermatology, 2005
- Tumid lupus erythematosus: Criteria for classification with immunohistochemical analysisArthritis Care & Research, 2003
- Histopathologic findings in lupus erythematosus tumidus: Review of 80 patientsJournal of the American Academy of Dermatology, 2003
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975